Soleno Therapeutics Inc. (SLNO)
42.49
-0.57 (-1.32%)
At close: Jan 14, 2025, 3:59 PM
43.00
1.20%
After-hours Jan 14, 2025, 05:29 PM EST
undefined% (undefined)
| Bid | 20 |
| Market Cap | 1.83B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -15.23 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 45.83 |
| Volume | 289,580 |
| Avg. Volume (20D) | 608,037 |
| Open | 43.67 |
| Previous Close | 43.06 |
| Day's Range | 41.98 - 43.97 |
| 52-Week Range | 36.61 - 60.92 |
| Beta | undefined |
About SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its n...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2014
Employees 33
Stock Exchange NASDAQ
Ticker Symbol SLNO
Website https://soleno.life
Analyst Forecast
According to 6 analyst ratings, the average rating for SLNO stock is "Buy." The 12-month stock price forecast is $72, which is an increase of 69.45% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+9.11%
Soleno Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
8 months ago ·
Source
+20.16%
Soleno Therapeutics shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.
